Kwang Hyub Han
Yonsei University
695 Papers
6.3K Citations
Kwang Hyub Han is an academic researcher from Yonsei University. The author has contributed to research in topics: Hepatocellular carcinoma & Medicine. The author has an hindex of 80, co-authored 692 publications. Previous affiliations of Kwang Hyub Han include University Health System.
Chat about Author
Papers
Independent imaging review (IIR) results in a phase 3 trial of lenvatinib (LEN) versus sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC).
Riccardo Lencioni,Masatoshi Kudo,Richard S. Finn,Shukui Qin,Kwang Hyub Han,Kenji Ikeda,Ann-Lii Cheng,Fabio Piscaglia,Guohong Han,Masafumi Ikeda,Krzysztof Simon,Dmitry Komov,Xuenong OuYang,T.R. Jeffry Evans,Max W. Sung,Terri A. Binder,Andrew Damon,Silvija Kraljevic,Min Ren,Baek-Yeol Ryoo +19 more
TL;DR: LEN showed treatment effect on OS by statistical demonstration of noninferiority to SOR in a phase 3 study in pts with uHCC, with significant improvement in median PFS, TTP, and ORR by mRECIST.
1
Hepatocellular carcinoma in Budd-Chiari syndrome: a single center experience with long-term follow-up in South Korea
Hana Park,Jin Young Yoon,Jun Yong Park,Chae Yoon Chon,Kwang Hyub Han,Sang Hoon Ahn,Do Young Kim,Kyeong Hye Park +7 more
- 01 Jan 2012
TL;DR: In this article, the authors evaluated long-term clinical course of Budd-Chiari syndrome (BCS) and predictive factors associated with the development of hepatocellular carcinoma (HCC) and survival.
1
•Journal Article
PREDICTORS OF PREMATURE WITHDRAWAL AND DOSE REDUCTIONS IN PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH PEGINTERFERON ALFA-2A (40KD) (PEGIFN alpha 2A) PLUS RIBAVIRIN IN A LARGE, MULTINATIONAL, OPEN-LABEL EXPANDED ACCESS PROGRAM
Samuel S. Lee,Yves Horsmans,Stuart K. Roberts,Hanna Berak,Geoffrey Dusheiko,Hugh Harley,Edward Gane,Petr Husa,Kwang Hyub Han,Stephanos J. Hadziyannis,E. Jenny Heathcote,Diethelm Messinger,Andreas Tietz,Peter Ferenci +13 more
1
Hepatitis B viral load to predict survival of HCC patients treated with sorafenib.
TL;DR: It was revealed that a high baseline HBV DNA level was an independent risk factor for worse overall survival, and rapid disease progression in a subgroup who did not receive antiviral prophylaxis with sorafenib (p=0.008), and viral reactivation occurred more frequently in patients who didNot receive pr...
1